Pfizer Inc. (NYSE:PFE) Shares Bought by Moors & Cabot Inc.

Moors & Cabot Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.4% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 225,301 shares of the biopharmaceutical company’s stock after purchasing an additional 15,569 shares during the period. Pfizer makes up approximately 0.9% of Moors & Cabot Inc.’s portfolio, making the stock its 21st biggest holding. Moors & Cabot Inc.’s holdings in Pfizer were worth $8,097,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Nuveen Asset Management LLC grew its position in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after purchasing an additional 34,544,423 shares during the period. Natixis acquired a new stake in Pfizer during the 2nd quarter worth about $258,466,000. Invesco Ltd. boosted its stake in shares of Pfizer by 14.6% during the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock worth $914,857,000 after acquiring an additional 2,693,349 shares in the last quarter. DNB Asset Management AS boosted its stake in shares of Pfizer by 241.0% during the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock worth $134,164,000 after acquiring an additional 2,638,873 shares in the last quarter. Finally, Thoroughbred Financial Services LLC boosted its stake in shares of Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after acquiring an additional 2,596,269 shares in the last quarter. 71.66% of the stock is currently owned by institutional investors.

Several research firms have recently issued reports on PFE. Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Bank of America began coverage on shares of Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price on the stock. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a research note on Wednesday, August 28th. Morgan Stanley lowered their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a research note on Tuesday, October 1st. Twelve analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average target price of $44.47.

In related news, major shareholder Pfizer Inc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Scott Gottlieb purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Pfizer stock traded up $0.18 during midday trading on Tuesday, reaching $36.64. The company had a trading volume of 8,294,205 shares, compared to its average volume of 16,028,038. The company has a market capitalization of $202.08 billion, a P/E ratio of 12.21, a P/E/G ratio of 2.16 and a beta of 0.66. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The firm’s fifty day simple moving average is $36.25 and its 200-day simple moving average is $39.64. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. Pfizer’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period last year, the company posted $0.77 EPS. On average, analysts expect that Pfizer Inc. will post 2.82 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is presently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a Roth IRA?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.